[
    [
        {
            "time": "2020-07-06",
            "original_text": "华大基因(300676.SZ)2020年度权益分派10派3.5元 股权登记日为7月6日",
            "features": {
                "keywords": [
                    "华大基因",
                    "权益分派",
                    "10派3.5元",
                    "股权登记日"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华大基因(300676.SZ)2020年度权益分派10派3.5元 股权登记日为7月6日",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-07-07",
            "original_text": "华大基因(300676.SZ)拟10股派3.5元 7月7日除权除息",
            "features": {
                "keywords": [
                    "华大基因",
                    "10股派3.5元",
                    "除权除息"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华大基因(300676.SZ)拟10股派3.5元 7月7日除权除息",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-04-15",
            "original_text": "美国Natera与华大基因携手打造肿瘤MRD检测技术Signatera正式进入中国市场",
            "features": {
                "keywords": [
                    "华大基因",
                    "Natera",
                    "Signatera",
                    "肿瘤MRD检测",
                    "中国市场"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "肿瘤检测"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "美国Natera与华大基因携手打造肿瘤MRD检测技术Signatera正式进入中国市场",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-04-15",
            "original_text": "肿瘤MRD检测技术Signatera/华见微正式进入中国",
            "features": {
                "keywords": [
                    "Signatera",
                    "华见微",
                    "肿瘤MRD检测",
                    "中国市场"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "肿瘤检测"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "肿瘤MRD检测技术Signatera/华见微正式进入中国",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-Q1",
            "original_text": "2021Q1医药行业重磅融资盘点：神州细胞加码生物药研发，信达生物融资46.71亿港元",
            "features": {
                "keywords": [
                    "医药行业",
                    "融资",
                    "神州细胞",
                    "信达生物",
                    "生物药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "融资"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2021Q1医药行业重磅融资盘点：神州细胞加码生物药研发，信达生物融资46.71亿港元",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]